Loss of Appetite in Adult Patients: Effectiveness and Safety of an Appetite Stimulating Medication in an Open-Label, Investigator-Initiated Study in India

Table 3

Summary of concomitant medication (safety population).

Class medication name, n (%)	Overall (N = 50)
Acetic acid derivatives and related substances	5 (10.0)
Aceclofenac	5 (10.0)
Angiotensin II receptor blockers	6 (12.0)
Olmesartan	1 (2.0)
Telmisartan	5 (10.0)
Anilides	5 (10.0)
Paracetamol	5 (10.0)
Selective beta-blocking agents	2 (4.0)
Atenolol	2 (4.0)
Biguanides	22 (44.0)
Metformin	22 (44.0)
Combinations of penicillins, including beta-lactamase inhibitors	1 (2.0)
Amoxicillin/potassium clavulanate	1 (2.0)
Dipeptidyl peptidase 4 inhibitors	8 (16.0)
Teneligliptin	8 (16.0)
Expectorants	3 (6.0)
Guaifenesin	3 (6.0)
HMG-CoA reductase inhibitors	1 (2.0)
Atrovastatin	1 (2.0)
Insulins and analogues for injection (intermediate- or long-acting combined with fast-acting)	1 (2.0)
Insulin	1 (2.0)
Leukotriene receptor antagonists	2 (4.0)
Montelukast	2 (4.0)
Mucolytics	3 (6.0)
Ambroxol	3 (6.0)
Multivitamins with minerals	1 (2.0)
Omega 3 fatty acids, green tea extract, Ginkgo, ginseng, antioxidant, vitamin, minerals	1 (2.0)
Multivitamins (other combinations)	9 (18.0)
Multivitamin	9 (18.0)
Platelet aggregation inhibitors excluding heparin	1 (2.0)
Aspirin	1 (2.0)
Selective beta 2-adrenoreceptor agonists	3 (6.0)
Terbutaline	3 (6.0)
Sulfonylureas	22 (44.0)
Glimepiride	22 (44.0)
Sulfur-containing imidazole derivatives	1 (2.0)
Carbimazole	1 (2.0)
Thiazides	5 (10.0)
Hydrochlorothiazide	5 (10.0)
Third-generation cephalosporins	4 (8.0)
Cefpodoxime	4 (8.0)
Thyroid hormones	5 (10.0)
Thyroxin	5 (10.0)
Vitamin D and analogues	4 (8.0)
Vitamin D3	4 (8.0)

Safety population consisted of all patients who received at least one dose of the study medication ATC, anatomical therapeutic chemical.